Drug Trial Radar · NCT07529717
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
May 18, 2026
Primary completion
Nov 17, 2027
Study completion Nov 17, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).
Conditions
- Metastatic Prostate Cancer
Interventions
AZD8359Drug
AZD8359 Monotherapy Administration route 1
AZD8359Drug
AZD8359 Monotherapy Administration route 2
AZD8359Drug
AZD8359 Monotherapy Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 1 (RDE1)
AZD8359Drug
AZD8359 Monotherapy Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 2 (RDE2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)Time frame: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
- Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Time frame: From first study dose to 21 OR 28 days post first dose based on schedule
- PSA response rate (Part B only)Time frame: Up to 3 years
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Orlando, Florida · Active not recruiting
Research Site
East Brunswick, New Jersey · Recruiting
Research Site
Hackensack, New Jersey · Withdrawn
Research Site
Providence, Rhode Island · Completed
Research Site
Darlinghurst, Australia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.